WO2008124081A2 - Dissolution rapide de produits de combinaison - Google Patents

Dissolution rapide de produits de combinaison Download PDF

Info

Publication number
WO2008124081A2
WO2008124081A2 PCT/US2008/004429 US2008004429W WO2008124081A2 WO 2008124081 A2 WO2008124081 A2 WO 2008124081A2 US 2008004429 W US2008004429 W US 2008004429W WO 2008124081 A2 WO2008124081 A2 WO 2008124081A2
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
oral dosage
triptan
nsaid
bicarbonate
Prior art date
Application number
PCT/US2008/004429
Other languages
English (en)
Other versions
WO2008124081A3 (fr
Inventor
Ilan Zalit
Uri Zadok
Original Assignee
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals Usa, Inc. filed Critical Teva Pharmaceutical Industries Ltd.
Priority to EP08742580A priority Critical patent/EP2029117A2/fr
Priority to CA002682872A priority patent/CA2682872A1/fr
Publication of WO2008124081A2 publication Critical patent/WO2008124081A2/fr
Publication of WO2008124081A3 publication Critical patent/WO2008124081A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formes de dosage orales pharmaceutiques à dissolution rapide de triptans et de AINS, des procédés de préparation de ceux-ci et des procédés de traitement au moyen de ceux-ci.
PCT/US2008/004429 2007-04-04 2008-04-03 Dissolution rapide de produits de combinaison WO2008124081A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP08742580A EP2029117A2 (fr) 2007-04-04 2008-04-03 Dissolution rapide de produits de combinaison
CA002682872A CA2682872A1 (fr) 2007-04-04 2008-04-03 Dissolution rapide de produits de combinaison

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US92203107P 2007-04-04 2007-04-04
US60/922,031 2007-04-04
US93261307P 2007-05-31 2007-05-31
US60/932,613 2007-05-31
US7056308P 2008-03-21 2008-03-21
US61/070,563 2008-03-21

Publications (2)

Publication Number Publication Date
WO2008124081A2 true WO2008124081A2 (fr) 2008-10-16
WO2008124081A3 WO2008124081A3 (fr) 2009-08-06

Family

ID=39530000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/004429 WO2008124081A2 (fr) 2007-04-04 2008-04-03 Dissolution rapide de produits de combinaison

Country Status (3)

Country Link
EP (1) EP2029117A2 (fr)
CA (1) CA2682872A1 (fr)
WO (1) WO2008124081A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009152551A1 (fr) * 2008-06-20 2009-12-23 Alphapharm Pty Ltd Formulation pharmaceutique
EP2387993A1 (fr) * 2010-05-21 2011-11-23 Sanovel Ilac Sanayi ve Ticaret A.S. Comprimés à désintégration orale de zolmitriptan et son procédé de préparation
CN102552423A (zh) * 2012-02-20 2012-07-11 许从玉 一种治疗偏头痛的药物组合物
GB2535257A (en) * 2014-09-09 2016-08-17 Charleston Laboratories Inc Pharmaceutical compositions
US9757455B2 (en) 2005-11-28 2017-09-12 Johnson & Johnson Consumer Inc. Oral therapeutic compound delivery system
US9775837B2 (en) 2008-01-09 2017-10-03 Charleston Laboratories, Inc. Pharmaceutical compositions
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
WO2019190433A2 (fr) 2017-12-15 2019-10-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques de flurbiprofène et d'agonistes du récepteur 5-ht1
WO2021133299A1 (fr) * 2019-12-27 2021-07-01 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Comprimés à désintégration orale comprenant du flurbiprofène et de l'élétriptan

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110492A2 (fr) * 2003-06-06 2004-12-23 Glaxo Group Limited Composition pharmaceutique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110492A2 (fr) * 2003-06-06 2004-12-23 Glaxo Group Limited Composition pharmaceutique

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757455B2 (en) 2005-11-28 2017-09-12 Johnson & Johnson Consumer Inc. Oral therapeutic compound delivery system
US10064856B2 (en) 2008-01-09 2018-09-04 Local Pharma, Inc. Pharmaceutical compositions
US9855264B2 (en) 2008-01-09 2018-01-02 Locl Pharma, Inc. Pharmaceutical compositions
US9789105B2 (en) 2008-01-09 2017-10-17 Locl Pharma, Inc. Pharmaceutical compositions
US9775837B2 (en) 2008-01-09 2017-10-03 Charleston Laboratories, Inc. Pharmaceutical compositions
AU2009260166B2 (en) * 2008-06-20 2014-10-09 Alphapharm Pty Ltd Pharmaceutical formulation
WO2009152551A1 (fr) * 2008-06-20 2009-12-23 Alphapharm Pty Ltd Formulation pharmaceutique
US8618157B2 (en) 2008-06-20 2013-12-31 Alphapharm Pty. Ltd. Pharmaceutical formulation
US8906949B2 (en) 2010-05-21 2014-12-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
EP2387993A1 (fr) * 2010-05-21 2011-11-23 Sanovel Ilac Sanayi ve Ticaret A.S. Comprimés à désintégration orale de zolmitriptan et son procédé de préparation
CN102552423A (zh) * 2012-02-20 2012-07-11 许从玉 一种治疗偏头痛的药物组合物
GB2535257A (en) * 2014-09-09 2016-08-17 Charleston Laboratories Inc Pharmaceutical compositions
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US10772840B2 (en) 2016-03-04 2020-09-15 Charleston Laboratories, Inc. Sumatriptan promethazine pharmaceutical compositions
WO2019190433A2 (fr) 2017-12-15 2019-10-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques de flurbiprofène et d'agonistes du récepteur 5-ht1
WO2019190433A3 (fr) * 2017-12-15 2019-12-19 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques de flurbiprofène et d'agonistes du récepteur 5-ht1
EP3723727A4 (fr) * 2017-12-15 2021-10-06 Sanovel Ilac Sanayi Ve Ticaret A.S. Compositions pharmaceutiques de flurbiprofène et d'agonistes du récepteur 5-ht1
WO2021133299A1 (fr) * 2019-12-27 2021-07-01 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Comprimés à désintégration orale comprenant du flurbiprofène et de l'élétriptan

Also Published As

Publication number Publication date
CA2682872A1 (fr) 2008-10-16
EP2029117A2 (fr) 2009-03-04
WO2008124081A3 (fr) 2009-08-06

Similar Documents

Publication Publication Date Title
US20090068262A1 (en) Rapid dissolution of combination products
WO2008124081A2 (fr) Dissolution rapide de produits de combinaison
JP4616009B2 (ja) ＮＳＡＩＤｓおよびトリプタンを含有する多層剤型
TWI466690B (zh) 塗膜錠劑調配物
KR100664479B1 (ko) 발데콕시브 조성물
US20070184109A1 (en) Compositions comprising triptans and nsaids
PT1017390E (pt) Comprimido revestido que compreende ácido nicotínico ou um composto metabolizado a ácido nicotínico sob uma forma de libertação prolongada, e um revestimento que contém um inibidor da hmg-coa-redutase sob uma forma de libertação imediata.
PT1448235E (pt) Composições farmacêuticas orais de libertação controlada de 5,8,14-triazatetraciclo ( 10.3.1.0(2,11).0(4,9) ) - hexadeca-2(11),3,5,7,9-pentaeno.
US20110008412A1 (en) Oral Formulations for 5-HT-Receptor Agonists, Uses and Methods of Treatment Employing The Same
CN102088966B (zh) 药物制剂
WO2014058046A1 (fr) Préparation pharmaceutique contenant un antagoniste calcique/un antagoniste des récepteurs de l'angiotensine ii
WO2005089720A1 (fr) Comprimes a base de valsartan et procede de preparation associe
WO2005082329A2 (fr) Procede de preparation de formes posologiques solides de valsartan et d'hydrochlorthiazide
AU2017248428A1 (en) Pharmaceutical formulation
CN117813089A (zh) 环氧合酶-2（cox-2）抑制剂组合物的制造方法
AU2013202529A1 (en) Pharmaceutical formulation
TW202200122A (zh) 二氟甲基鳥氨酸及舒林酸（ｓｕｌｉｎｄａｃ），固定劑量組合調配物
MXPA05013201A (en) Composition comprising triptans and nsaids

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008742580

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742580

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2682872

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE